3 results
Approved WMORecruiting
We hypothesize that Kenalog-40, Kenalog-10 and Depo-Medrol 40 mg/ml have a different effectiveness in treating trigger fingers in both primary as secondary outcomes.
Approved WMOPending
This is a first-in-human Phase Ia/Ib, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary anti-tumor activity of RO7502175 as a single…
Approved WMOPending
This is a first-in-human Phase Ia/Ib, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary anti-tumor activity of RO7502175 as a single…